Implications of pharmacogenetics for individualizing drug treatment and for study design (Q35102211)

6 August 2017

1 reference

title

Implications of pharmacogenetics for individualizing drug treatment and for study design (English)

1 reference

Przemysław M. Mrozikiewicz

6 August 2017

4

object named as

Przemyslaw M Mrozikiewicz

1 reference

6 August 2017

Christian Meisel

1

1 reference

6 August 2017

Thomas Gerloff

2

1 reference

6 August 2017

Julia Kirchheiner

3

1 reference

6 August 2017

Przemyslaw Niewinski

5

1 reference

6 August 2017

Jürgen Brockmöller

6

1 reference

6 August 2017

Ivar Roots

7

1 reference

6 August 2017

15 March 2003

1 reference

Journal of Molecular Medicine

6 August 2017

1 reference

6 August 2017

81

1 reference

6 August 2017

3

1 reference

6 August 2017

154-167

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-002-0417-4

6 August 2017

0 references

cites work

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Enzymatic Deficiency in Primaquine-Sensitive Erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Polymorphic hydroxylation of Debrisoquine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

The P450 gene superfamily: recommended nomenclature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

21 January 2018

12 December 2020

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

An inventory of the human ABC proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

A general pattern for substrate recognition by P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Association of a human G-protein beta3 subunit variant with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Replication validity of genetic association studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Use of unlinked genetic markers to detect population stratification in association studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

How to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

A common polymorphism associated with antibiotic-induced cardiac arrhythmia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

PlA2 polymorphism and efficacy of aspirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

The Substrate Binding Site of Human Liver Cytochrome P450 2C9: An Approach Using Designed Tienilic Acid Derivatives and Molecular Modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-002-0417-4

Reduced inhibition by abciximab in platelets with the PlA2 polymorphism

21 January 2018

1 reference

12 December 2020

Predicting the cytochrome P450 mediated metabolism of xenobiotics.

1 reference

12 December 2020

Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase)

1 reference

12 December 2020

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

1 reference

12 December 2020

Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

1 reference

12 December 2020

ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans

1 reference

12 December 2020

Effect of CYP2C polymorphisms on the pharmacokinetics of phenytoin in Japanese patients with epilepsy

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism

1 reference

12 December 2020

Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences

1 reference

12 December 2020

Allelic and functional variability of cytochrome P4502C9.

1 reference

12 December 2020

The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis

1 reference

12 December 2020

Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells.

1 reference

12 December 2020

1 reference

12 December 2020

Genetic association between sensitivity to warfarin and expression of CYP2C9*3

1 reference

12 December 2020

Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.

1 reference

12 December 2020

Enzymatic deficiency in primaquine-sensitive erythrocytes

1 reference

12 December 2020

Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure

1 reference

12 December 2020

Pharmacogenetics of tolbutamide metabolism in humans

1 reference

12 December 2020

Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine.

1 reference

12 December 2020

The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.

1 reference

12 December 2020

Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene

1 reference

12 December 2020

Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus

1 reference

12 December 2020

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates

1 reference

12 December 2020

Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population.

1 reference

12 December 2020

Pharmacogenetic applications of the Human Genome project

1 reference

12 December 2020

Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

1 reference

12 December 2020

A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations

1 reference

12 December 2020

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans

1 reference

12 December 2020

PROLONGED HYPOGLYCEMIA SECONDARY TO TOLBUTAMIDE

1 reference

12 December 2020

Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists

1 reference

12 December 2020

The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells

1 reference

12 December 2020

P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs

1 reference

12 December 2020

Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition

1 reference

12 December 2020

MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects

1 reference

12 December 2020

10.1007/S00109-002-0417-4

Identifiers

DOI

1 reference

6 August 2017

1 reference